ARID1A and cancer: Altogether, of 62,851 cancer patients with ≥1 cfDNA alteration in the blood, 3137 (5%) had ≥1 deleterious ARID1A alteration (a frequency similar to the ~6% generally reported in tissue sequencing), suggesting this non-invasive test’s value in detecting ARID1A.